International Waldenstrom’s Macroglobulinemia Foundation



The following new clinical trials are currently open in the US to patients with WM. Details about each of these trials can be found at is external) by entering the trial identification number in the “ Search for Studies” box.

New Clinical Trial for Relapsed/Refractory CLL and Indolent B-Cell Lymphoma Patients Utilizes CAR Modified T-Cell Immunotherapy – Patients with relapsed, refractory, or residual WM are eligible to be included in a Phase I/IIa clinical trial at Memorial Sloan Kettering Cancer Center that includes a single dose of cyclophosphamide preconditioning followed by an infusion of 19-28z CAR modified autologous T-cells. (Trial identification number NCT00466531).

Novel Proteasome Inhibitor Ixazomib Enters Phase II Trial in Combination Therapy for WM Patients – Dana-Farber Cancer Institute is opening a Phase II trial for the combination of ixazomib, dexamethasone, and rituximab in previously untreated WM patients. (Trial identification number NCT02400437).

Zydelig (Idelalisib) to Enter Phase II Trial for Relapsed/Refractory WM – Dana-Farber Cancer Institute is scheduled to open a Phase II trial of Zydelig (also called idelalisib, GS-1101, or CAL-101) in May for relapsed/refractory WM. (Trial identification number NCT02439138).

Idera Pharmaceuticals Expects to Add Additional Patients to Phase I/II Trial of IMO-8400 in Relapsed/Refractory WM – As part of the ongoing Phase I/II clinical trial of IMO-8400 in relapsed/refractory WM, Idera Pharmaceuticals has enrolled the targeted number of patients at each of the three dose levels to fulfill the requirements for a data review by an independent safety data monitoring committee. In June, Idera expects to open an additional cohort to allow more patients to enroll in the study. (Trial identification number NCT02092909).


  • 6144 Clark Center Ave.
    Sarasota, FL 34238
  • Phone: 941-927-4963
  • Fax: 941-927-4467
  • [email protected]